4.5 Article

Associations of Anxiety with Amyloid, Tau, and Neurodegeneration in Older Adults without Dementia: A Longitudinal Study

期刊

JOURNAL OF ALZHEIMERS DISEASE
卷 82, 期 1, 页码 273-283

出版社

IOS PRESS
DOI: 10.3233/JAD-210020

关键词

Alzheimer's disease; amyloid-beta; anxiety; biomarkers; dementia; neurodegeneration; tauopathies

资金

  1. National Key R&D Program of China [2018YFC1314702]
  2. Shanghai Municipal Science and Technology Major Project [2018SHZDZX01]
  3. ZHANGJIANG LAB, Tianqiao
  4. State Key Laboratory of Neurobiology and Frontiers Center for Brain Science of Ministry of Education, Fudan University
  5. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  6. DOD ADNI (Department of Defense) [W81XWH-12-2-0012]
  7. National Institute on Aging
  8. National Institute of Biomedical Imaging and Bioengineering
  9. AbbVie
  10. Alzheimer's Association
  11. Alzheimer's Drug Discovery Foundation
  12. Araclon Biotech
  13. BioClinica, Inc.
  14. Biogen
  15. Bristol-Myers Squibb Company
  16. CereSpir, Inc.
  17. Cogstate
  18. Eisai Inc.
  19. Elan Pharmaceuticals, Inc.
  20. Eli Lilly and Company
  21. EuroImmun
  22. F. HoffmannLa Roche Ltd
  23. Genentech, Inc.
  24. Fujirebio
  25. GE Healthcare
  26. IXICO Ltd.
  27. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  28. Johnson & Johnson Pharmaceutical Research & Development LLC.
  29. Lumosity
  30. Lundbeck
  31. Merck Co., Inc.
  32. Meso Scale Diagnostics, LLC.
  33. NeuroRx Research
  34. Neurotrack Technologies
  35. Novartis Pharmaceuticals Corporation
  36. Pfizer Inc.
  37. Piramal Imaging
  38. Servier
  39. Takeda Pharmaceutical Company
  40. Transition Therapeutics
  41. The Canadian Institutes of Health Research
  42. Chrissy Chen Institute

向作者/读者索取更多资源

Anxiety is associated with amyloid-beta deposition and neurodegeneration in non-dementia elderly, while anxiety in MCI patients predicts conversion to dementia. Anxiety may have a selective role in predicting disease progression in the early phase of AD.
Background: The pathophysiological process of amyloid-beta, tau deposition, and neurodegeneration of Alzheimer's disease (AD) begin in a preclinical phase, while anxiety is associated with an increased risk of AD in preclinical phase. Objective: To examine the relationships between anxiety and amyloid-beta, tau deposition, and neurodegeneration. To test the hypothesis that anxiety could predict clinical progression in the elderly without dementia. Methods: 1,400 participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database were included in the study and were studied over a median period of 3 years. In multivariable models, the cross-sectional and longitudinal associations between anxiety and amyloid-beta PET, tau PET, and FDG PET SUVRs in participants without dementia were explored using Spearman rank correlation, logistic regression model, multiple linear regression model, Kaplan-Meier survival curves, and Cox proportional hazards model. The association between baseline anxiety and clinical progression was also explored. Results: There was a positive correlation between anxiety and amyloid-beta deposition (r = 0.11, p = 0.0017) and a negative correlation between anxiety and neurodegeneration (r = - 0.13, p = 0.00022). MCI participants with anxiety showed a faster clinical progression of dementia (HR = 1.56, p = 0.04). Non-anxious participants with more amyloid-beta deposition or more severe neurodegeneration displayed accelerated development into anxiety (HR = 2.352, p < 0.0001; HR= 2.254, p < 0.0001). Conclusion: Anxiety was associated with amyloid-beta deposition and neurodegeneration in non-dementia elderly. Anxiety in MCI predicted conversion to dementia. Anxiety may play a selective role and prediction of disease progression in the early phase of AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据